TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07293351: ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC)

Sponsor: Bristol-Myers Squibb · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 474 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$2,159,850

Rescue Site Savings

+$1,413,720

Unlock Full NCT07293351 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07293351 Rescue Dossier →